StoxAlkem Laboratories vs Biocon: share price & financials comparison
NSE: ALKEM vs BIOCON · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Alkem Laboratories vs Biocon at a glance
Alkem Laboratories (ALKEM) has a market capitalisation of ₹63,326 Cr, against ₹59,497 Cr for Biocon (BIOCON). Over the past year Biocon has returned -2.3%, compared with -4.3% for Alkem Laboratories. On valuation, Alkem Laboratories trades at a lower P/E of 29.4 versus 131.6. Alkem Laboratories earns a higher return on equity (15.6% vs 1.3%). Alkem Laboratories comes out ahead on size, valuation, profitability, growth, financial health and technicals. Across the scored metrics below, Alkem Laboratories leads on 12 and Biocon on 6. On StoxGud's 10-point checklist, Alkem Laboratories scores 6/10 and Biocon scores 3/10.
| Metric | Alkem Laboratories | Biocon |
|---|---|---|
| Size | ||
| Market cap | ₹63,326 Cr | ₹59,497 Cr |
| Revenue (latest FY) | ₹14,712 Cr | ₹16,927 Cr |
| Net profit (latest FY) | ₹2,302 Cr | ₹386 Cr |
| Valuation | ||
| P/E | 29.4 | 131.6 |
| P/B | 4.58 | 1.71 |
| Dividend yield | 0.97% | 0.15% |
| Profitability | ||
| Return on equity | 15.6% | 1.3% |
| Net profit margin | 14.3% | 2.6% |
| Operating margin | 20.1% | 20.3% |
| Growth | ||
| Revenue growth (YoY) | +10.9% | +2.2% |
| Net profit growth (YoY) | -21.7% | -51.1% |
| Revenue CAGR (multi-year) | +9.9% | +19.0% |
| Financial health | ||
| Debt to equity | 0.12 | 0.43 |
| Momentum | ||
| 1-month return | -1.0% | +1.4% |
| 1-year return | -4.3% | -2.3% |
| 3-year CAGR | +11.5% | +17.5% |
| 5-year CAGR | +8.0% | +0.9% |
| 10-year CAGR | +13.0% | +9.3% |
| Distance from 52W high | -10.1% | -17.2% |
| Technicals | ||
| RSI (14) | 71 | 59 |
| Price vs 200-day avg | -2.4% | -6.4% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Alkem Laboratories | Biocon |
|---|---|---|
| Price above 50-day average | ✓ | ✗ |
| Price above 200-day average | ✗ | ✗ |
| 50-day average above 200-day (uptrend) | ✗ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✓ |
| Positive 1-year return | ✗ | ✗ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✗ |
| Score | 6/10 | 3/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Alkem Laboratories or Biocon?
Alkem Laboratories has a market cap of ₹63,326 Cr and Biocon has a market cap of ₹59,497 Cr as of 06 Nov 2026.
Which has a lower P/E, Alkem Laboratories or Biocon?
Alkem Laboratories has the lower P/E: Alkem Laboratories trades at 29.4 and Biocon at 131.6.
Which gave better returns in the last year, Alkem Laboratories or Biocon?
Biocon did better: Alkem Laboratories returned -4.3% and Biocon returned -2.3% over one year.
Is Alkem Laboratories or Biocon a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Alkem Laboratories scores 6/10 and Biocon scores 3/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.